Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | MARK3 | P27448 | 1/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372626 | 1.00 | LRRK2 (0.48) | LRRK2CHEK1AURKAPDPK1CHEK2 | |
| SCHEMBL546176 | 0.84 | CHEK1 (0.32) | LRRK2CHEK1AURKAPDPK1CHEK2 | |
| SCHEMBL31439406 | 0.84 | LRRK2 (0.54) | LRRK2CHEK1AURKAPDPK1CHEK2 | |
| SCHEMBL17372625 | 0.83 | TARS1 (0.31) | JAK2JAK1JAK3 | |
| SCHEMBL17372629 | 0.83 | TARS1 (0.31) | JAK2JAK1JAK3 | |
| SCHEMBL25292763 | 0.83 | CHEK1 (0.45) | LRRK2CHEK1AURKAPDPK1CHEK2 | |
| SCHEMBL28696556 | 0.81 | LRRK2 (0.45) | LRRK2CHEK1AURKAPDPK1CHEK2 | |
| SCHEMBL17372559 | 0.76 | NPC1 (0.55) | HSD17B10SMN1; SMN2BRD4TP53TSHR | |
| SCHEMBL29638101 | 0.76 | NPC1 (0.55) | HSD17B10SMN1; SMN2BRD4TP53TSHR | |
| SCHEMBL23748507 | 0.76 | NPC1 (0.55) | HSD17B10SMN1; SMN2BRD4TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111452-A2 | CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025111430-A1 | CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4337331-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | The Broad Institute Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2023141474-A9 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| WO-2022241045-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4728076-A1 | METHOD FOR STABILIZING RNA | Pfizer Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4687992-A1 | LIPID-BASED NANOPARTICLE TARGETED AT ACTIVATED IMMUNE CELLS FOR THE EXPRESSION OF IMMUNE CELL INHIBITING MOLECULE AND USE THEREOF | OSE IMMUNOTHERAPEUTICS (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4687991-A1 | LIPID-BASED NANOPARTICLE TARGETED AT ACTIVATED IMMUNE CELLS FOR THE EXPRESSION OF IMMUNE CELL ENHANCING MOLECULE AND USE THEREOF | OSE IMMUNOTHERAPEUTICS (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4665390-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | Pfizer Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4658809-A1 | CAPPING ASSAY | Seqirus Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025202834-A1 | POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF | PFIZER INC. (US) | 2025-10-02 | — | — | WO | disclosed |
| EP-4333880-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | Pfizer Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4243790-A1 | ENHANCED FORMULATION STABILIZATION AND IMPROVED LYOPHILIZATION PROCESSES | BioNTech SE (DE) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023111907-A1 | POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF | PFIZER INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20220362372-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | PFIZER INC. | 2022-11-17 | — | — | US | disclosed |
| WO-2022234417-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | PFIZER INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022234416-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022234405-A1 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | PFIZER INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022101461-A1 | ENHANCED FORMULATION STABILIZATION AND IMPROVED LYOPHILIZATION PROCESSES | BioNTech SE (DE) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362372-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | RNASEH1, HAVCR2, HNRNPH3 | LRRK2 3021/4885CHEK1 3894/4885AURKA 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.